Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health

Core Insights - Haleon is investing £65 million in a new oral health manufacturing plant in Shanghai to enhance its presence in China's gum health market, which is valued at approximately £860 million [1] - The company aims to expand its gum health brand parodontax to 30 cities in China by the end of 2027, targeting a rising middle class with increasing disposable income [1] - Haleon's investment reflects its long-term commitment to improving the health and wellbeing of Chinese consumers through locally tailored products and enhanced manufacturing capabilities [1] Investment and Expansion - The new manufacturing facility will support the expansion of Haleon's oral care portfolio, including global brands like Sensodyne and parodontax, into tier 2 and tier 3 cities in China [1] - Haleon plans to reach over 250 million people through its distribution strategy, which includes e-commerce platforms and retail pharmacies [1] - The investment is part of a broader strategy to respond quickly to evolving consumer preferences and accelerate innovation in the oral care category [1] Product Development - parodontax is the first clinically proven toothpaste in China targeting the root cause of bleeding gums, with a unique sensory profile adapted for local consumers [1] - Haleon's global R&D team collaborated with local scientists to modify the product's flavor and packaging to better appeal to Chinese consumers [1] - The company is focused on delivering high-quality, science-backed products that align with the growing demand for preventative oral care solutions [1] Strategic Priorities - China is identified as a strategic priority for Haleon, with the company aiming to combine global research expertise with local insights to enhance product offerings [1] - The new facility in Shanghai's Lingang New Area will enable Haleon to build a more agile and efficient supply chain, supporting its ambition to reach one billion more consumers by 2030 [1] - Haleon completed the acquisition of its TSKF joint venture in June 2025, further solidifying its position in China's consumer healthcare market [1]